Table 1.

Baseline patient characteristics

CharacteristicSunitinib (n = 243)Placebo (n = 118)
Age, y
    Median5755
    Range23-8423-81
Sex, n (%)
    Male152 (63)71 (60)
    Female91 (37)47 (40)
ECOG PS, n (%)
    0109 (45)53 (45)
    1131 (54)63 (53)
    23 (1)2 (2)
Time since original diagnosis, y
    Median3.23.3
    Range0.2-26.80.2-16.4
Tumor burden,* mm
    Median227240
    Range18-72229-749
Previous imatinib therapy
    Maximum daily dose, mg
        Median800800
        Range300-1,600400-1,600
    Cumulative treatment duration, wk
        Median107108
        Range0.3-20611-231
    Treatment outcome, n (%)
        Progression ≤6 mo42 (17)20 (17)
        Progression >6 mo188 (77)94 (80)
        Intolerance13 (5)4 (3)
  • *Sum of the longest diameters of target lesions.